Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Patients without human immunodeficiency virus (HIV) are increasingly recognized as being at risk for cryptococcosis. Knowledge of characteristics of cryptococcosis in these patients remains incomplete.

Methods: We conducted a retrospective study of cryptococcosis in 46 Australian and New Zealand hospitals to compare its frequency in patients with and without HIV and describe its characteristics in patients without HIV. Patients with cryptococcosis between January 2015 and December 2019 were included.

Results: Of 475 patients with cryptococcosis, 90% were without HIV (426 of 475) with marked predominance in both Cryptococcus neoformans (88.7%) and Cryptococcus gattii cases (94.3%). Most patients without HIV (60.8%) had a known immunocompromising condition: cancer (n = 91), organ transplantation (n = 81), or other immunocompromising condition (n = 97). Cryptococcosis presented as incidental imaging findings in 16.4% of patients (70 of 426). The serum cryptococcal antigen test was positive in 85.1% of tested patients (319 of 375); high titers independently predicted risk of central nervous system involvement. Lumbar puncture was performed in 167 patients to screen for asymptomatic meningitis, with a positivity rate of 13.2% where meningitis could have been predicted by a high serum cryptococcal antigen titer and/or fungemia in 95% of evaluable cases. One-year all-cause mortality was 20.9% in patients without HIV and 21.7% in patients with HIV (P = .89).

Conclusions: Ninety percent of cryptococcosis cases occurred in patients without HIV (89% and 94% for C. neoformans and C. gattii, respectively). Emerging patient risk groups were evident. A high level of awareness is warranted to diagnose cryptococcosis in patients without HIV.

Download full-text PDF

Source
http://dx.doi.org/10.1093/cid/ciad321DOI Listing

Publication Analysis

Top Keywords

patients hiv
28
patients
15
hiv
9
patients human
8
human immunodeficiency
8
immunodeficiency virus
8
cryptococcosis
8
cryptococcosis patients
8
patients cryptococcosis
8
immunocompromising condition
8

Similar Publications

Background: Mobile health (mHealth) interventions can be effective for people living with HIV, who are sensitive to privacy breach risks. Understanding the perceived experiences of intervention participants can provide comprehensive insights into potential users and predict intervention effectiveness. Thus, it is necessary to plan engagement measurement and consider ways to enhance engagement during the app development phase.

View Article and Find Full Text PDF

Background: Acute viral respiratory infections (AVRIs) rank among the most common causes of hospitalisation worldwide, imposing significant healthcare burdens and driving the development of pharmacological treatments. However, inconsistent outcome reporting across clinical trials limits evidence synthesis and its translation into clinical practice. A core outcome set (COS) for pharmacological treatments in hospitalised adults with AVRIs is essential to standardise trial outcomes and improve research comparability.

View Article and Find Full Text PDF

BackgroundDolutegravir (DTG)-based antiretroviral treatment is now the recommended regimen because of its high efficacy and fewer adverse effects. Nonetheless, hyperglycemia as adverse effect of DTG was reported in few clinical observations.MethodsA case-control study was carried out among DTG-based antiretroviral therapy (ART) users during the study period.

View Article and Find Full Text PDF

Kaposi sarcoma (KS) is an angioproliferative malignancy associated with human herpesvirus 8 (HHV-8) infection, predominantly affecting immunocompromised patients such as those with HIV/AIDS. Despite advances in antiretroviral therapy, KS remains a significant cause of morbidity and mortality in this population, especially when diagnosis or treatment is delayed. Ocular involvement, although rare, can lead to significant functional impairment.

View Article and Find Full Text PDF

Background: The global spread of antimicrobial resistance (AMR) in threatens empiric single-dose gonorrhoea treatment. Enhanced global AMR surveillance is imperative. We report i) gonococcal antimicrobial susceptibility and resistance data from 2023 in the World Health Organization Enhanced Gonococcal Antimicrobial Surveillance Programme (WHO EGASP) in the WHO Western Pacific Region (Cambodia, the Philippines, Viet Nam), Southeast Asian Region (Indonesia, Thailand), and African Region (Malawi, South Africa, Uganda, Zimbabwe), and ii) metadata of the gonorrhoea patients.

View Article and Find Full Text PDF